|
End-of-day quote
Mexican S.E.
2026-09-10
|
5-day change | 1st Jan Change | ||
| 2,453.18 MXN | -1.08% |
|
0.00% | +10.39% |
| 09-18 | Dr. Reddy's Confirms License for Gilead's Yearly-Once HIV Drug; Shares Up 2% | MT |
| 09-16 | Gilead Sciences Insider Sold Shares Worth $432,646, According to a Recent SEC Filing | MT |
Company Valuation: Gilead Sciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 91,081 | 107,677 | 100,942 | 115,118 | 152,281 | 186,130 | - | - |
| Change | - | 18.22% | -6.25% | 14.04% | 32.28% | 22.23% | - | - |
| Enterprise Value (EV) 1 | 118,530 | 126,522 | 118,665 | 131,838 | 169,585 | 202,875 | 195,254 | 188,964 |
| Change | - | 6.74% | -6.21% | 11.1% | 28.63% | 19.63% | -3.76% | -3.22% |
| P/E | 14.7x | 23.6x | 18x | 243x | 18.1x | -45.4x | 18.7x | 17.2x |
| PBR | 4.32x | 5.05x | 4.48x | 5.98x | 6.73x | 11.2x | 8.25x | 6.45x |
| PEG | - | -0.9x | 0.8x | -2.7x | 0x | 0x | -0x | 2.02x |
| Capitalization / Revenue | 3.34x | 3.95x | 3.72x | 4x | 5.17x | 6.06x | 5.7x | 5.42x |
| EV / Revenue | 4.34x | 4.64x | 4.38x | 4.59x | 5.76x | 6.61x | 5.97x | 5.5x |
| EV / EBITDA | 8.12x | 8.86x | 9.01x | 11.7x | 10.6x | 25.8x | 10.9x | 10.3x |
| EV / EBIT | 9.45x | 10.4x | 11.3x | 15.5x | 12.9x | 62.6x | 12.3x | 11.2x |
| EV / FCF | 11x | 15.2x | 16x | 12.8x | 17.9x | -385x | 14.9x | 13.6x |
| FCF Yield | 9.12% | 6.59% | 6.25% | 7.82% | 5.58% | -0.26% | 6.69% | 7.34% |
| Dividend per Share 2 | 2.84 | 2.92 | 3 | 3.08 | 3.16 | 3.291 | 3.349 | 3.012 |
| Rate of return | 3.91% | 3.4% | 3.7% | 3.33% | 2.57% | 2.19% | 2.23% | 2.01% |
| EPS 2 | 4.93 | 3.64 | 4.5 | 0.38 | 6.78 | -3.306 | 8.024 | 8.707 |
| Distribution rate | 57.6% | 80.2% | 66.7% | 811% | 46.6% | -99.5% | 41.7% | 34.6% |
| Net sales 1 | 27,305 | 27,281 | 27,116 | 28,754 | 29,443 | 30,702 | 32,682 | 34,347 |
| EBITDA 1 | 14,598 | 14,283 | 13,177 | 11,287 | 15,953 | 7,859 | 17,834 | 18,324 |
| EBIT 1 | 12,548 | 12,180 | 10,484 | 8,520 | 13,193 | 3,240 | 15,834 | 16,889 |
| Net income 1 | 6,225 | 4,592 | 5,665 | 480 | 8,510 | -4,275 | 10,275 | 10,917 |
| Net Debt 1 | 27,449 | 18,845 | 17,723 | 16,720 | 17,304 | 16,745 | 9,125 | 2,835 |
| Reference price 2 | 72.61 | 85.85 | 81.01 | 92.37 | 122.74 | 150.11 | 150.11 | 150.11 |
| Nbr of stocks (in thousands) | 1,254,384 | 1,254,244 | 1,246,042 | 1,246,266 | 1,240,680 | 1,239,955 | - | - |
| Announcement Date | 2/1/22 | 2/2/23 | 2/6/24 | 2/11/25 | 2/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.78x | 11.92x | 24.16x | 0.6% | 1,028B | |
| 30.03x | 6.68x | 18.7x | 1.99% | 651B | |
| 33.38x | 7.81x | 16.15x | 2.6% | 466B | |
| 19.33x | 4.72x | 11.71x | 2.81% | 346B | |
| 19.72x | 5.16x | 12.79x | 3.11% | 266B | |
| 21.26x | 4.42x | 12.58x | 1.99% | 259B | |
| 24.43x | 6.42x | 11.43x | 2.62% | 208B | |
| 12.52x | 4.56x | 9.46x | 4.01% | 191B | |
| -45.4x | 6.61x | 25.81x | 2.19% | 186B | |
| Average | 16.45x | 6.48x | 15.87x | 2.44% | 400.19B | |
| Weighted average by Cap. | 23.68x | 7.73x | 17.83x | 1.99% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GILD Stock
- GILD * Stock
- Valuation Gilead Sciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
